We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aiming for Alzheimer’s, Lilly Spins off Neuroscience Unit
Aiming for Alzheimer’s, Lilly Spins off Neuroscience Unit
Eli Lilly’s biologics division, Lilly Bio-Medicines, is splitting into two distinct units, one of which will focus entirely on approved and phase 3 drugs for pain and neurodegeneration — including Alzheimer’s disease.